Pluristem

Israeli breakthrough company seeks to use cells to improve quality of life

The biotechnology company Pluri, is expanding its activities and establishing strategic collaborations for the development and marketing of food-tech and pharmaceutical products.

 THE CELL expansion process takes place in Pluri’s clean rooms.
 Haim Gavrieli, Chairman of the Tnuva Group.

Israel's Tnuva partners with Pluristem to develop cultured cell-based meat

Biologists work in a laboratory at Pluristem Theraputics in Haifa

Israel: The 'Start-Up Nation' is now the 'Biotech Nation' - opinion

Yaky Yanay, CEO of Pluristem, speaks at the Global Investment Forum

Pluristem CEO touts a new generation of medical treatments


Israeli COVID-19 treatment shows 100% survival rate - preliminary data

Not only have all the patients survived, according to Pluristem, but four of them showed improvement in respiratory parameters.

Biologists work in a laboratory at Pluristem Therapeutics Inc. in Haifa

Pluristem’s potential new breakthrough

Haifa company weeks away from presenting clinical trial results that could ‘generate hope’ for patients suffering from untreatable vascular disease.

Biologists work in a laboratory at Pluristem Therapeutics Inc. in Haifa

Smart cells that heal

Innovative Israeli cell therapy could step up treatment of CLI.

Lars Norgren, emeritus professor at Örebro University in Sweden, and a member of the CLI study steering committee; Prof. Nikol Sigrid senior consultant of the Department of Clinical and Interventional Angiology at the St. Georg Asklepios Hospital in Hamburg, Germany and Pluristem co-CEO Zami Aberman

New hope for cancer patients

Cancer is a leading cause of death around the world and its incidence continues to rise. Each year around 12.7 million people discover they have cancer and 7.6 million people die from it.

Pluristen chairman and co-CEO Zami Aberman holds a vial of specialized stem cells the company calls ‘the next generation of biological therapeutic products

USFDA clears Plursitem for expanded access program

Patients suffering from critical limb ischemia can now benefit without being part of clinical trials

A Pluristem scientist at work.

The Israeli company developing radiation countermeasures for the US government

Imagine a scenario where cells and tissues can be engineered to secrete a range of therapeutic proteins that can help the body generate its own healing process.

DAVID RUBIN: What came out of this terrorist attack, where we were left for dead, what had to come out of it was something much greaterA PLURISTEM clean room, part of their manufacturing lab